StockNews.com Initiates Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research note published on Wednesday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

Titan Pharmaceuticals stock opened at $6.70 on Wednesday. Titan Pharmaceuticals has a 1-year low of $5.00 and a 1-year high of $16.60. The stock’s fifty day moving average is $7.32 and its two-hundred day moving average is $7.09.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.